Loading
companiesCompany
Lantheus
Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.
Also called: Progenics Pharmaceuticals, Inc.ProgenicsMolecular Insight Pharmaceuticals, Inc.Molecular Insight Pharmaceuticals
Overview
Lantheus, based in Bedford, Massachusetts, and listed as LNTH, makes Pylarify, or piflufolastat F-18, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026. Its portfolio also includes Neuraceq for amyloid imaging, PNT2002, a 177Lu-PSMA-I&T therapy whose SPLASH phase 3 missed overall survival, and PNT2003, a generic 177Lu-DOTATATE, and OnCo also links it to iobenguane I-131 and samarium-153 lexidronam. It connects to prostate cancer, to PET tracer manufacturing and distribution and radionuclide generators, and to Evergreen Theragnostics. Whether an imaging leader can become a therapy company after SPLASH is the open question. Piflufolastat F-18 has its own page.
Headquarters
Bedford, MA, US
Scorecard
All companies#125of 1244 companies, score 44
- approved products +12
- phase 3 +3
- targets +2
- modalities +4
- regions +3
- 24-month regulatory events +2
- registry trials +18
2 approved, 1 in phase 3, 0 earlier, 1 targets, 85 registry studies. Formula on the scorecards page.
Type
Radiopharmaceuticals · LNTH
Stage
Public
Website
ApprovedPET imaging agent
Piflufolastat F-18 / Pylarify TruVu · Pylarify
Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026.
EstablishedRadioligand therapy (beta, norepinephrine transporter)
131I-MIBG (iobenguane I-131) therapy · Azedra
High-dose radioactive MIBG delivers radiation from inside neuroblastoma cells that take up noradrenaline; used for relapsed disease and tested in upfront therapy. A branded high-specific-activity form, Azedra, was approved for phaeochromocytoma and paraganglioma in 2018 and discontinued in 2024.
Phase 3Radioligand therapy (beta)
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
ApprovedBone-seeking therapeutic radiopharmaceutical (beta emitter)
Samarium-153 lexidronam · Quadramet
Quadramet (samarium-153 lexidronam) is a radioactive bone-seeking injection that lodges in bone metastases and irradiates them from inside, approved in 1997 to relieve pain from prostate, breast and other cancers spread to bone. Most patients get relief within one to two weeks, but marrow suppression follows at three to five weeks, and radium-223 and PSMA radioligands have largely replaced it.
Similar pages
- CompanyCurium
Shares Samarium-153 lexidronam, 177Lu-PSMA-I&T, Radionuclide generators and cold kits, Piflufolastat F-18 / Pylarify TruVu.
- CompanyPETNET Solutions (Siemens Healthineers)
Shares PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyCardinal Health Nuclear & Precision Health Solutions
Shares PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyTelix Pharmaceuticals
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- TechnologyResearch reactors for medical isotopes (Mo-99, Lu-177, I-131)
Shares 177Lu-PSMA-I&T, Radionuclide generators and cold kits, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyIRE (Institut national des Radioéléments)
Shares Radionuclide generators and cold kits, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- CompanyJubilant Radiopharma
Shares PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- TechnologyMedical cyclotrons, hot cells, and synthesis modules
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
cancers
fronts
technologies
drugs
EstablishedRadioligand therapy (beta, norepinephrine transporter)
131I-MIBG (iobenguane I-131) therapy · Azedra
Phase 3Radioligand therapy (beta)
ApprovedPET imaging agent
Piflufolastat F-18 / Pylarify TruVu · Pylarify
ApprovedBone-seeking therapeutic radiopharmaceutical (beta emitter)
Samarium-153 lexidronam · Quadramet